Plasma renin and cardiovascular risk: What is the evidence for an association?

Cardiology (Switzerland)

Volumn 125, Issue 1, 2013, Pages 50-59

  Volpe, Massimo ^a,b   Unger, Thomas ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Cardiovascular risk; Direct renin inhibitors; Plasma renin

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN; RENIN INHIBITOR; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DIURETIC THERAPY; ENZYME ACTIVITY; HOMEOSTASIS; HUMAN; HYPERTENSION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRESSOR RESPONSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 84876798157     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000348365     Document Type: Review

References (69)

1. Laragh JH, Sealey JE: The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens 2011; 24: 1164-1180.
2. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-449.
3. Buhler FR, Laragh JH, Baer L, Vaughan ED, Brunner HR: Propranolol inhibition of renin secretion. N Engl J Med 1972; 287: 1209-1214.
4. Buhler FR, Laragh JH, Vaughan ED, Brunner HR, Gavras H, Baer L: Antihypertensive action of propranolol: specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 1973; 32: 511-522.
5. Laragh Method: The Laragh method ® for correcting the BP of patients with uncontrolled hypertension. http://www.laraghmethod. org.
6. Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH: Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009; 22: 792-801.
7. Alderman MH, Cohen HW, Sealey JE, Laragh JH: Pressor responses to antihypertensive drug types. Am J Hypertens 2010; 23: 1031-1037.
8. Laragh JH, Baer L, Brunner HR, Buhler FR, Vaughan JE: Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52: 633-652.
9. Unger T, Ganten D, Lang RE: Tissue converting enzyme and cardiovascular actions of converting enzyme inhibitors. J Cardiovasc Pharmacol 1986; 8(suppl 10):S75-S81.
10. Daimon M, Konta T, Oizumi T, Karasawa S, Kaino W, Takase K, Jimbu Y, Wada K, Kameda W, Susa S, Saito T, Kubota I, Kayama T, Kato T: Higher plasma renin activity is a risk factor for total mortality in older Japanese individuals: the Takahata study. Metabolism 2012; 61: 504-511.
11. Meade T: Review: plasma renin and the incidence of cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010; 11: 91-98.
12. Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, Levy D, Benjamin EJ, Kannel WB, Vasan RS: Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 2007; 28: 2644-2652.
13. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-1104.
14. Gonzalez MC, Cohen HW, Sealey JE, Laragh JH, Alderman MH: Enduring direct association of baseline plasma renin activity with allcause and cardiovascular mortality in hypertensive patients. Am J Hypertens 2011; 24: 1181-1186.
15. Muhlestein JB, May HT, Bair TL, Prescott MF, Horne BD, White R, Anderson JL: Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol 2010; 106: 764-769.
16. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-591.
17. Verma S, Gupta M, Holmes DT, Xu L, Teoh H, Gupta S, Yusuf S, Lonn EM: Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2011; 32: 2135-2142.
18. Masson S, Solomon S, Angelici L, Latini R, Anand IS, Prescott M, Maggioni AP, Tognoni G, Cohn JN: Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2010; 16: 964-970.
19. Vergaro G, Emdin M, Iervasi A, Zyw L, Gabutti A, Poletti R, Mammini C, Giannoni A, Fontana M, Passino C: Prognostic value of plasma renin activity in heart failure. Am J Cardiol 2011; 108: 246-251.
20. Volpe M, Francia P, Tocci G, Rubattu S, Cangianiello S, Elena Rao MA, Trimarco B, Condorelli M: Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study. Clin Cardiol 2010; 33: 700-707.
21. Aoki A, Ogawa T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Nitta K: Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients. Heart Vessels 2010; 25: 195-202.
22. Jones MR, Sealey JE, Laragh JH: Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007; 20: 907-916.
23. Lijnen P, Fagard R, Staessen J, Amery A: Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol 1981; 12: 387-392.
24. Petretta M, Bonaduce D, Marciano F, Bianchi V, Valva G, Apicella C, de Luca N, Gisonni P: Effect of 1 year of lisinopril treatment on cardiac autonomic control in hypertensive patients with left ventricular hypertrophy. Hypertension 1996; 27: 330-338.
25. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
26. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
27. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST, Chapman AB: Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens 2008; 21: 61-66.
28. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, Anderson RJ: Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy: Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 1998; 280: 1168-1172.
29. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR: Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010; 23: 1014-1022.
30. Alderman MH, Cohen HW, Sealey JE, Laragh JH: Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17: 1-7.
31. Blaufox M: Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. JAMA 1992; 267: 1221-1225.
32. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J: Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo-the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-921.
33. Pitkajarvi T, Ylitalo P, Metsa-Ketela T, Vapaatalo H: The effects of a beta 1-blocking agent, atenolol, on blood pressure, plasma renin activity and prostaglandin F2 alpha excretion in patients with essential hypertension. Acta Med Scand 1979; 206: 107-113.
34. Gibbs CR, Beevers DG, Lip GYH: The management of hypertensive disease in Black patients. QJM 1999; 92: 187-192.
35. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH: Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999; 12: 451-459.
36. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140.
37. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FDR, Krum H, Maggioni A, McKelvie RS, Pina IL, Soler-Soler J, Swedberg K: Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005; 7: 710-721.
38. Kubon C, Mistry NB, Grundvold I, Halvorsen S, Kjeldsen SE, Westheim AS: The role of beta-blockers in the treatment of chronic heart failure. Trends Pharmacol Sci 2011; 32: 206-212.
39. Ferrario CM, Strawn WB: Role of the reninangiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-128.
40. Funke-Kaiser H, Zollmann FS, Schefe JH, Unger T: Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens Res 2010; 33: 98-104.
41. Song R, Yosypiv IV: (Pro)renin receptor in kidney development and disease. Int J Nephrol 2011; 2011: 247048.
42. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M: Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47: 894-900.
43. Hirose T, Hashimoto M, Totsune K, Metoki H, Asayama K, Kikuya M, Sugimoto K, Katsuya T, Ohkubo T, Hashimoto J, Rakugi H, Takahashi K, Imai Y: Association of (pro)renin receptor gene polymorphism with blood pressure in Japanese men: the Ohasama study. Am J Hypertens 2009; 22: 294-299.
44. Hirose T, Hashimoto M, Totsune K, Metoki H, Hara A, Satoh M, Kikuya M, Ohkubo T, Asayama K, Kondo T, Kamide K, Katsuya T, Ogihara T, Izumi S, Rakugi H, Takahashi K, Imai Y: Association of (pro)renin receptor gene polymorphisms with lacunar infarction and left ventricular hypertrophy in Japanese women: the Ohasama study. Hypertens Res 2011; 34: 530-535.
45. Danser AH: Novel drugs targeting hypertension: renin inhibitors. J Cardiovasc Pharmacol 2007; 50: 105-111.
46. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, Pandolfi PP, Ruiz P, Unger T, Funke-Kaiser H: A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99: 1355-1366.
47. Meade TW, Cooper JA, Peart WS: Plasma renin activity and ischemic heart disease. N Engl J Med 1993; 329: 616-619.
48. Chan C, Poulter N, Scanlon M, Whitehouse A, Welsh P, Sattar N, Sever P: The Anglo-Sandinavian Cardia Outcomes Trial (ASCOT) biomarker programme. J Hypertens 2011; 29(e-suppl A):e17.
49. Sever PS, Chang CL, Prescott MF, Gupta A, Poulter NR, Whitehouse A, Scanlon M: Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Eur Heart J 2012; 33: 2970-2979.
50. Unger T: Risk factors: plasma renin activity predicts renal impairment. Nat Rev Nephrol 2012; 8: 686-687.
51. Tomaschitz A, Pilz S, Ritz E, Morganti A, Grammer T, Amrein K, Boehm BO, Marz W: Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J 2011; 32: 2642-2649.
52. Francis GS: Pathophysiology of chronic heart failure. Am J Med 2001; 110(suppl 7A):37S-46S.
53. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigators. N Engl J Med 1992; 327: 685-691.
54. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.
55. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM: Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-1219.
56. The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
57. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39:E1-E8.
58. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15: 3126-3133.
59. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A: Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20.
60. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-229.
61. Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J: Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008; 24: 1039-1047.
62. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G, Hui F, Satlin A: Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-200.
63. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, Beyene J, Shah PS: The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 2012; 344:e42.
64. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213.
65. McMurray JJ, Abraham WT, Dickstein K, Kober L, Massie BM, Krum H: Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012; 14: 341-343.
66. Aliskiren Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/021985s023lbl.pdf (accessed November 16, 2012).
67. Highlights of Prescribing Information. http://www.pharma.us.novartis.com/product/pi/pdf/tekturna.pdf (accessed November 16, 2012).
68. Apperloo AJ, de Zeeuw D, de Jong PE: A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51: 793-797.
69. Adiyaman A, Staessen JA: Renin turning full circle as cardiovascular risk factor. Eur Heart J 2007; 28: 2557-2558.